Titre : Antigènes CD8

Antigènes CD8 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Probability
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Antigènes CD8 : Questions médicales les plus fréquentes", "headline": "Antigènes CD8 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Antigènes CD8 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-14", "dateModified": "2025-04-08", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Antigènes CD8" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Antigènes de différenciation des lymphocytes T", "url": "https://questionsmedicales.fr/mesh/D000945", "about": { "@type": "MedicalCondition", "name": "Antigènes de différenciation des lymphocytes T", "code": { "@type": "MedicalCode", "code": "D000945", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.101.100.894" } } }, "about": { "@type": "MedicalCondition", "name": "Antigènes CD8", "alternateName": "CD8 Antigens", "code": { "@type": "MedicalCode", "code": "D016827", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Ramon Arens", "url": "https://questionsmedicales.fr/author/Ramon%20Arens", "affiliation": { "@type": "Organization", "name": "Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands." } }, { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Dora Hammerl", "url": "https://questionsmedicales.fr/author/Dora%20Hammerl", "affiliation": { "@type": "Organization", "name": "Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands. d.hammerl@erasmusmc.nl." } }, { "@type": "Person", "name": "Reno Debets", "url": "https://questionsmedicales.fr/author/Reno%20Debets", "affiliation": { "@type": "Organization", "name": "Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands." } }, { "@type": "Person", "name": "Bingjie Zhang", "url": "https://questionsmedicales.fr/author/Bingjie%20Zhang", "affiliation": { "@type": "Organization", "name": "New York Genome Center, New York, NY, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Management of neonates at risk of early onset sepsis: a probability-based approach and recent literature appraisal : Update of the Swiss national guideline of the Swiss Society of Neonatology and the Pediatric Infectious Disease Group Switzerland.", "datePublished": "2024-10-17", "url": "https://questionsmedicales.fr/article/39417838", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00431-024-05811-0" } }, { "@type": "ScholarlyArticle", "name": "Splenectomy and azygoportal disconnection decreases the risk of hepatocellular carcinoma for cirrhosis patients with portal hypertension bleeding: a 10-year retrospective follow-up study based on the inverse probability of treatment weighting method.", "datePublished": "2023-03-21", "url": "https://questionsmedicales.fr/article/36943530", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00535-023-01982-z" } }, { "@type": "ScholarlyArticle", "name": "Impact of three-dimensional reconstruction visualization technology on short-term and long-term outcomes after hepatectomy in patients with hepatocellular carcinoma: a propensity-score-matched and inverse probability of treatment-weighted multicenter study.", "datePublished": "2024-03-01", "url": "https://questionsmedicales.fr/article/38241321", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/JS9.0000000000001047" } }, { "@type": "ScholarlyArticle", "name": "Comparison of Survival Outcomes Between Larynx-Preserving Open Partial Pharyngectomy and Radiotherapy or Chemoradiotherapy in Patients with Hypopharyngeal Squamous Cell Carcinoma: A Single-Center Retrospective Analysis with Inverse Probability of Treatment Weighting Adjustments.", "datePublished": "2023-07-14", "url": "https://questionsmedicales.fr/article/37452169", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1245/s10434-023-13934-1" } }, { "@type": "ScholarlyArticle", "name": "Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis.", "datePublished": "2024-04-29", "url": "https://questionsmedicales.fr/article/38756630", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.21037/jgo-24-218" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Marqueurs biologiques", "item": "https://questionsmedicales.fr/mesh/D015415" }, { "@type": "ListItem", "position": 4, "name": "Antigènes de différenciation", "item": "https://questionsmedicales.fr/mesh/D000943" }, { "@type": "ListItem", "position": 5, "name": "Antigènes de différenciation des lymphocytes T", "item": "https://questionsmedicales.fr/mesh/D000945" }, { "@type": "ListItem", "position": 6, "name": "Antigènes CD8", "item": "https://questionsmedicales.fr/mesh/D016827" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Antigènes CD8 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Antigènes CD8", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Antigènes CD8", "description": "Comment diagnostiquer une déficience en antigènes CD8 ?\nQuels tests sont utilisés pour évaluer les antigènes CD8 ?\nLes antigènes CD8 sont-ils liés à des maladies spécifiques ?\nPeut-on mesurer les antigènes CD8 dans les tissus ?\nQuel rôle jouent les antigènes CD8 dans le diagnostic du cancer ?", "url": "https://questionsmedicales.fr/mesh/D016827?mesh_terms=Probability&page=272#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Antigènes CD8", "description": "Quels symptômes indiquent une anomalie des CD8 ?\nLes symptômes varient-ils selon le type de lymphocytes T ?\nComment les CD8 affectent-ils la réponse aux infections ?\nY a-t-il des symptômes associés à une suractivation des CD8 ?\nLes symptômes d'une déficience en CD8 sont-ils visibles ?", "url": "https://questionsmedicales.fr/mesh/D016827?mesh_terms=Probability&page=272#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Antigènes CD8", "description": "Comment prévenir les anomalies des CD8 ?\nLes infections peuvent-elles affecter les CD8 ?\nY a-t-il des mesures préventives pour les maladies auto-immunes ?\nLes examens réguliers aident-ils à prévenir les problèmes CD8 ?\nL'exercice physique influence-t-il les CD8 ?", "url": "https://questionsmedicales.fr/mesh/D016827?mesh_terms=Probability&page=272#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Antigènes CD8", "description": "Quels traitements ciblent les antigènes CD8 ?\nPeut-on renforcer les CD8 par des médicaments ?\nComment traiter une déficience en CD8 ?\nLes vaccins influencent-ils les CD8 ?\nQuels effets secondaires des traitements CD8 ?", "url": "https://questionsmedicales.fr/mesh/D016827?mesh_terms=Probability&page=272#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Antigènes CD8", "description": "Quelles complications peuvent survenir avec des CD8 anormaux ?\nLes CD8 anormaux augmentent-ils le risque de cancer ?\nComment les CD8 affectent-ils la transplantation d'organes ?\nLes complications des CD8 peuvent-elles être traitées ?\nY a-t-il des complications liées aux traitements des CD8 ?", "url": "https://questionsmedicales.fr/mesh/D016827?mesh_terms=Probability&page=272#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Antigènes CD8", "description": "Quels facteurs augmentent le risque d'anomalies CD8 ?\nLe mode de vie influence-t-il les CD8 ?\nLes infections virales sont-elles un facteur de risque pour les CD8 ?\nLe stress impacte-t-il les CD8 ?\nY a-t-il des prédispositions génétiques pour les anomalies CD8 ?", "url": "https://questionsmedicales.fr/mesh/D016827?mesh_terms=Probability&page=272#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une déficience en antigènes CD8 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic se fait par analyse sanguine pour évaluer la population de lymphocytes T CD8." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer les antigènes CD8 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests de cytométrie en flux permettent de quantifier les lymphocytes T CD8 dans le sang." } }, { "@type": "Question", "name": "Les antigènes CD8 sont-ils liés à des maladies spécifiques ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies des antigènes CD8 sont associées à des maladies auto-immunes et des infections virales." } }, { "@type": "Question", "name": "Peut-on mesurer les antigènes CD8 dans les tissus ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des biopsies peuvent être analysées pour détecter la présence de lymphocytes T CD8." } }, { "@type": "Question", "name": "Quel rôle jouent les antigènes CD8 dans le diagnostic du cancer ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les antigènes CD8 sont souvent évalués pour déterminer l'immunité antitumorale dans les cancers." } }, { "@type": "Question", "name": "Quels symptômes indiquent une anomalie des CD8 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des infections récurrentes et des signes d'auto-immunité peuvent indiquer une anomalie des CD8." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type de lymphocytes T ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier selon que les lymphocytes T sont CD4 ou CD8, affectant la réponse immunitaire." } }, { "@type": "Question", "name": "Comment les CD8 affectent-ils la réponse aux infections ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les lymphocytes T CD8 sont essentiels pour éliminer les cellules infectées par des virus et des tumeurs." } }, { "@type": "Question", "name": "Y a-t-il des symptômes associés à une suractivation des CD8 ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Une suractivation peut entraîner des symptômes d'auto-immunité, comme la fatigue et des douleurs articulaires." } }, { "@type": "Question", "name": "Les symptômes d'une déficience en CD8 sont-ils visibles ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Non, les symptômes ne sont pas toujours visibles, mais des infections fréquentes peuvent être un signe." } }, { "@type": "Question", "name": "Comment prévenir les anomalies des CD8 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une bonne hygiène, des vaccinations et un mode de vie sain peuvent aider à prévenir les anomalies." } }, { "@type": "Question", "name": "Les infections peuvent-elles affecter les CD8 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines infections peuvent altérer la fonction des lymphocytes T CD8, augmentant le risque de maladies." } }, { "@type": "Question", "name": "Y a-t-il des mesures préventives pour les maladies auto-immunes ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Éviter le stress et maintenir une alimentation équilibrée peuvent réduire le risque de maladies auto-immunes." } }, { "@type": "Question", "name": "Les examens réguliers aident-ils à prévenir les problèmes CD8 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des examens réguliers peuvent détecter précocement des anomalies des lymphocytes T CD8." } }, { "@type": "Question", "name": "L'exercice physique influence-t-il les CD8 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut améliorer la fonction immunitaire, y compris celle des CD8." } }, { "@type": "Question", "name": "Quels traitements ciblent les antigènes CD8 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les immunothérapies, comme les inhibiteurs de points de contrôle, ciblent les lymphocytes T CD8 dans le cancer." } }, { "@type": "Question", "name": "Peut-on renforcer les CD8 par des médicaments ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments immunomodulateurs peuvent augmenter l'activité des lymphocytes T CD8." } }, { "@type": "Question", "name": "Comment traiter une déficience en CD8 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement peut inclure des thérapies géniques ou des transfusions de lymphocytes T CD8." } }, { "@type": "Question", "name": "Les vaccins influencent-ils les CD8 ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les vaccins peuvent stimuler la réponse des lymphocytes T CD8 contre des pathogènes spécifiques." } }, { "@type": "Question", "name": "Quels effets secondaires des traitements CD8 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure des réactions auto-immunes et des inflammations." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des CD8 anormaux ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des infections graves et des maladies auto-immunes dues à une réponse immunitaire altérée." } }, { "@type": "Question", "name": "Les CD8 anormaux augmentent-ils le risque de cancer ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une fonction CD8 altérée peut réduire la surveillance immunitaire, augmentant le risque de cancer." } }, { "@type": "Question", "name": "Comment les CD8 affectent-ils la transplantation d'organes ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des CD8 anormaux peuvent entraîner un rejet d'organe en raison d'une réponse immunitaire inappropriée." } }, { "@type": "Question", "name": "Les complications des CD8 peuvent-elles être traitées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des traitements immunosuppresseurs peuvent aider à gérer les complications liées aux CD8." } }, { "@type": "Question", "name": "Y a-t-il des complications liées aux traitements des CD8 ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent entraîner des effets secondaires comme des infections opportunistes." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque d'anomalies CD8 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme l'âge avancé, les maladies chroniques et l'immunosuppression augmentent le risque." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il les CD8 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent affecter la fonction des CD8." } }, { "@type": "Question", "name": "Les infections virales sont-elles un facteur de risque pour les CD8 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines infections virales peuvent altérer la fonction des lymphocytes T CD8." } }, { "@type": "Question", "name": "Le stress impacte-t-il les CD8 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut affaiblir la réponse immunitaire, y compris celle des CD8." } }, { "@type": "Question", "name": "Y a-t-il des prédispositions génétiques pour les anomalies CD8 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines conditions génétiques peuvent prédisposer à des anomalies des lymphocytes T CD8." } } ] } ] }

Sources (2731 au total)

Management of neonates at risk of early onset sepsis: a probability-based approach and recent literature appraisal : Update of the Swiss national guideline of the Swiss Society of Neonatology and the Pediatric Infectious Disease Group Switzerland.

In Switzerland and other high-income countries, one out of 3000 to 5000 term and late preterm neonates develops early onset sepsis (EOS) associated with a mortality of around 3%, while incidence and m... This guideline, developed through a critical review of the literature, facilitates a probability-based approach to the management of neonates at risk of early onset sepsis.... • Neonatal exposure to antibiotics is disproportionally high compared with the incidence of early onset sepsis with implications for future health and antimicrobial resistance.... • A probability-based approach may facilitate a more balanced management of neonatal sepsis and antibiotic stewardship....

Splenectomy and azygoportal disconnection decreases the risk of hepatocellular carcinoma for cirrhosis patients with portal hypertension bleeding: a 10-year retrospective follow-up study based on the inverse probability of treatment weighting method.

Liver cirrhosis is the highest risk factor for hepatocellular carcinoma (HCC) worldwide. However, etiological therapy is the only option in cirrhosis patients to decrease the HCC risk. The aim of this... Between April 2012 and April 2021, we identified 595 CPH patients in our hepatobiliary pancreatic center who were diagnosed with gastroesophageal variceal bleeding and secondary hypersplenism, and per... According to the method of therapy, patients were divided into LSD (n = 345) and endoscopic therapy (ET; n = 250) groups. Kaplan-Meier analysis revealed that patients who underwent LSD had higher surv... Considering the better postoperative survival and the ability to prevent HCC in CPH patients with gastroesophageal variceal bleeding and secondary hypersplenism, LSD is worth popularization in situati...

Impact of three-dimensional reconstruction visualization technology on short-term and long-term outcomes after hepatectomy in patients with hepatocellular carcinoma: a propensity-score-matched and inverse probability of treatment-weighted multicenter study.

Three-dimensional reconstruction visualization technology (3D-RVT) is an important tool in the preoperative assessment of patients undergoing liver resection. However, it is not clear whether this tec... A total of 3402 patients from five centers were consecutively enrolled from January 2016 to December 2020, and grouped based on the use of 3D-RVT or 2D imaging for preoperative assessment. Baseline ch... A total of 1681 patients underwent 3D-RVT assessment before hepatectomy (3D group), while 1721 patients used 2D assessment (2D group). The PSM cohort included 892 patient pairs. In the IPTW cohort, th... In this multicenter study, perioperative outcomes and RFS of HCC patients following 3D-RVT assessment were significantly different from those following 2D imaging assessment. Thus, 3D-RVT may be a fea...

Comparison of Survival Outcomes Between Larynx-Preserving Open Partial Pharyngectomy and Radiotherapy or Chemoradiotherapy in Patients with Hypopharyngeal Squamous Cell Carcinoma: A Single-Center Retrospective Analysis with Inverse Probability of Treatment Weighting Adjustments.

There is a group of hypopharyngeal squamous cell carcinoma (HPSCC) patients for whom larynx-preserving open partial pharyngectomy (PP) and radiotherapy/chemoradiotherapy (RT/CRT) are indicated. We aim... This study evaluated HPSCC patients who were initially treated by PP or RT/CRT at our institution between January 2007 and October 2019. Overall survival (OS), disease-specific survival (DSS), larynge... Overall, 198 patients were enrolled; 63 and 135 underwent PP and RT/CRT, respectively. IPTW-adjusted 5-year OS, DSS, LFS, and LRFS rates in the PP and RT/CRT groups were 84.3% and 61.9% (p = 0.019), 8... Despite the risk of bias related to unadjusted factors, our results suggest that PP is associated with significantly better OS and LFS compared with RT/CRT for HPSCC....

Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis.

While surufatinib, sunitinib, and everolimus have shown efficacy for advanced neuroendocrine neoplasms (NENs) in randomized controlled trials (RCTs), direct comparisons in a real-world setting remain ... A retrospective, observational study was conducted at Fudan University Shanghai Cancer Center, including patients with advanced NENs treated with surufatinib, sunitinib, or everolimus between July 202... The study enrolled 123, 56, and 68 locally advanced or metastatic NEN patients treated with surufatinib, sunitinib, and everolimus, respectively. Before adjusting for confounding factors, surufatinib ... In a real-world Chinese cohort, surufatinib significantly outperformed sunitinib and everolimus in prolonging PFS among advanced NEN patients, with identifiable clinical features impacting survival, a...

A glycosylated hemoglobin A1c above 6% (42 mmol/mol) is associated with a high risk of developing Cystic Fibrosis-Related Diabetes and a lower probability of weight gain in both adults and children with Cystic Fibrosis.

The classical glycosylated hemoglobin A1c threshold of 6.5% is an insensitive screening test for cystic fibrosis-related diabetes (CFRD). We sought to identify CF-specific A1C thresholds associated wi... We studied the cross sectional and longitudinal associations between A1c, BMI, and FEV1 in 2 cohorts of 223 children (followed for up to 8 years) and 289 adults (followed for a mean of 7.5 ± 4.3 years... For the onset of OGTT-defined CFRD optimal A1c threshold was 5.9% in adults (sensitivity: 67% and specificity: 71%) and 5.7% for children (sensitivity: 60% and specificity: 47%). Kaplan-Meier analysis... An A1C above 6% may be associated with a high risk of developing CFRD and a lower probability of weight gain in both adults and children with CF....

Proteomic profiling reveals KRT6C as a probable hereterodimer partner for KRT9: New insights into re-classifying epidermolytic palmoplantar keratoderma (EPPK) and a milder form of pachyonychia congenita (PC-K6c) as a group of genetic cutaneous disorders.

Epidermolytic palmoplantar keratoderma (EPPK), a highly penetrant autosomal dominant genodermatosis, is characterized by diffuse keratoses on palmplantar epidermis. The keratin 9 gene (KRT9) is respon...

Cluster-Based Toxicity Estimation of Osteoradionecrosis via Unsupervised Machine Learning: Moving Beyond Single Dose-Parameter Normal Tissue Complication Probability by Using Whole Dose-Volume Histograms for Cohort Risk Stratification.

Given the limitations of extant models for normal tissue complication probability estimation for osteoradionecrosis (ORN) of the mandible, the purpose of this study was to enrich statistical inference... The analysis was conducted on retrospective data of 1,259 head and neck cancer (HNC) patients treated at XXX between 2005 and 2015. During a minimum 12-month post-therapy follow-up period, 173 patient... The K-means clustering method identified six clusters among the DVHs. Based on the first five clusters, the dose-volume space was partitioned by the soft-margin SVM into distinct regions with differen... This study presents an unsupervised-learning analysis of a large-scale data set to evaluate the risk of mandibular ORN among HNC patients. The results provide a visual risk-assessment tool for ORN (ba...

Long-term oral administration of Huaier granules improves survival outcomes in hepatocellular carcinoma patients within Milan criteria following microwave ablation: a propensity score matching and stabilized inverse probability weighting analysis.

This study aimed to elucidate the therapeutic effects of Huaier granules on hepatocellular carcinoma (HCC) within the Milan criteria in patients who underwent microwave ablation (MWA).... A total of 228 patients were included, with 97 in the Huaier group and 131 in the control group. We evaluated progression-free survival (PFS), overall survival (OS), and extrahepatic metastasis surviv... Following PSM, the 1-, 3-, and 5-year PFS rates in the Huaier and control groups were 83.5% vs 70.7%, 57.7% vs 42.6%, and 43.6% vs 31.9% (... Huaier granules can reduce the risk of recurrence and improve the OS of patients with HCC within the Milan criteria following MWA. Administering Huaier granules for over 6 months proved beneficial....